Dynamic Technology Lab Private Ltd Raises Stake in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Dynamic Technology Lab Private Ltd increased its stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) by 260.7% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 44,419 shares of the company’s stock after buying an additional 32,104 shares during the quarter. Dynamic Technology Lab Private Ltd’s holdings in GoodRx were worth $308,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in GDRX. California State Teachers Retirement System grew its position in shares of GoodRx by 5.1% during the 1st quarter. California State Teachers Retirement System now owns 70,912 shares of the company’s stock valued at $503,000 after acquiring an additional 3,444 shares during the period. Liontrust Investment Partners LLP bought a new position in GoodRx during the second quarter valued at $520,000. Legato Capital Management LLC purchased a new stake in GoodRx in the second quarter worth $805,000. Picton Mahoney Asset Management raised its stake in shares of GoodRx by 24.3% in the second quarter. Picton Mahoney Asset Management now owns 607,090 shares of the company’s stock valued at $4,736,000 after buying an additional 118,703 shares during the period. Finally, ClariVest Asset Management LLC lifted its position in shares of GoodRx by 27.4% during the 2nd quarter. ClariVest Asset Management LLC now owns 195,722 shares of the company’s stock valued at $1,527,000 after buying an additional 42,097 shares during the last quarter. Institutional investors own 63.77% of the company’s stock.

GoodRx Stock Performance

NASDAQ:GDRX opened at $4.84 on Monday. GoodRx Holdings, Inc. has a twelve month low of $4.09 and a twelve month high of $9.26. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. The stock has a market cap of $1.84 billion, a P/E ratio of -161.33, a PEG ratio of 3.52 and a beta of 1.39. The business’s 50-day moving average price is $5.98 and its two-hundred day moving average price is $7.25.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on GDRX. UBS Group decreased their price objective on GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a report on Friday, August 9th. Citigroup lowered their price target on shares of GoodRx from $10.00 to $7.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. Barclays cut their price objective on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a report on Monday, November 11th. Raymond James raised shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 target price on the stock in a report on Friday, August 9th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 price target on shares of GoodRx in a report on Friday, August 16th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $8.86.

Insider Activity at GoodRx

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total value of $83,921.22. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 4.17% of the stock is currently owned by insiders.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.